|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
103,650,000 |
Market
Cap: |
1.54(B) |
Last
Volume: |
772,336 |
Avg
Vol: |
1,689,102 |
52
Week Range: |
$11.5 - $17.51 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 604 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s primary product, Firdapse®, is used for the treatment of adult patients (ages 17 and above) with Lambert-Eaton, Myasthenic Syndrome, a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs. Co. has developed its vigabatrin (CPP-109) as a generic version of Sabril®. Co. has an agreement with Endo International plc's subsidiary, Endo Ventures Limited, for the development and commercialization of generic Sabril® tablets through Endo's U.S. Generic Pharmaceuticals segment, Par Pharmaceutical.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
50,000 |
304,000 |
330,151 |
4,223,516 |
Total Sell Value |
$803,000 |
$4,338,050 |
$4,684,028 |
$62,649,148 |
Total People Sold |
2 |
6 |
7 |
12 |
Total Sell Transactions |
2 |
8 |
9 |
53 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ingenito Gary |
Chief Med. & Reg. Officer |
|
2023-12-06 |
4 |
OE |
$1.13 |
$56,500 |
D/D |
50,000 |
88,367 |
|
- |
|
Miller Steve |
Chief Op. & Scientific Officer |
|
2023-12-05 |
4 |
S |
$14.24 |
$569,600 |
D/D |
(40,000) |
647,457 |
|
-9% |
|
Denkhaus Donald A |
Director |
|
2023-08-03 |
4 |
OE |
$1.13 |
$67,800 |
D/D |
60,000 |
393,000 |
|
- |
|
Del Carmen Jeffrey |
Chief Commercial Officer |
|
2023-06-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,942) |
13,599 |
|
- |
|
Del Carmen Jeffrey |
Chief Commercial Officer |
|
2023-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
17,541 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2023-05-16 |
4 |
OE |
$0.79 |
$137,341 |
D/D |
173,849 |
4,119,285 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2023-05-15 |
4 |
S |
$13.23 |
$345,978 |
D/D |
(26,151) |
3,945,436 |
|
8% |
|
Mcenany Patrick J |
President and CEO |
|
2023-05-15 |
4 |
OE |
$0.79 |
$20,659 |
D/D |
26,151 |
3,971,587 |
|
- |
|
Daly Richard J |
Director |
|
2023-05-12 |
4 |
OE |
$0.79 |
$39,500 |
D/D |
50,000 |
148,000 |
|
- |
|
Tierney David S |
Director |
|
2023-05-11 |
4 |
OE |
$0.79 |
$15,800 |
D/D |
20,000 |
333,541 |
|
- |
|
Miller Steve |
Chief Operating Officer |
|
2023-05-11 |
4 |
OE |
$0.79 |
$79,000 |
D/D |
100,000 |
687,457 |
|
- |
|
Coelho Philip H |
Director |
|
2023-05-04 |
4 |
OE |
$0.79 |
$39,500 |
D/D |
50,000 |
204,887 |
|
- |
|
Tierney David S |
Director |
|
2023-04-05 |
4 |
S |
$16.83 |
$504,900 |
D/D |
(30,000) |
313,541 |
|
12% |
|
Tierney David S |
Director |
|
2023-04-05 |
4 |
OE |
$0.79 |
$23,700 |
D/D |
30,000 |
343,541 |
|
- |
|
Del Carmen Jeffrey |
Chief Commercial Officer |
|
2023-03-29 |
4 |
S |
$16.69 |
$667,810 |
D/D |
(40,000) |
7,541 |
|
14% |
|
Del Carmen Jeffrey |
Chief Commercial Officer |
|
2023-03-29 |
4 |
OE |
$2.24 |
$127,063 |
D/D |
40,000 |
26,558 |
|
- |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-29 |
4 |
S |
$16.67 |
$835,100 |
D/D |
(50,000) |
50,557 |
|
14% |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-29 |
4 |
OE |
$1.13 |
$56,500 |
D/D |
50,000 |
100,557 |
|
- |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-28 |
4 |
S |
$16.37 |
$962,786 |
D/D |
(58,216) |
50,557 |
|
15% |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-28 |
4 |
OE |
$0.79 |
$45,991 |
D/D |
58,216 |
108,773 |
|
- |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-22 |
4 |
S |
$16.41 |
$689,528 |
D/D |
(41,784) |
50,557 |
|
15% |
|
Grande Alicia |
VP, Treasurer and CFO |
|
2023-03-22 |
4 |
OE |
$0.79 |
$33,009 |
D/D |
41,784 |
89,081 |
|
- |
|
Elsbernd Brian |
Chief Compliance/Legal Officer |
|
2023-03-20 |
4 |
S |
$16.07 |
$803,450 |
D/D |
(50,000) |
138,076 |
|
15% |
|
Elsbernd Brian |
Chief Compliance/Legal Officer |
|
2023-03-20 |
4 |
OE |
$1.13 |
$56,500 |
D/D |
50,000 |
188,076 |
|
- |
|
Del Carmen Jeffrey |
Chief Commercial Officer |
|
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,125) |
7,541 |
|
- |
|
312 Records found
|
|
Page 3 of 13 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|